Anti cd38 v450

Manufactured by BD

The Anti-CD38 V450 is a laboratory product that can be used to detect and analyze CD38 protein expression. It provides a fluorescent signal that allows for the identification and enumeration of cells expressing the CD38 antigen.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Anti-CD38 (23 citations) CD38 V450 (7 citations)

3 protocols using anti cd38 v450

Multiparametric Flow Cytometry Immunophenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were mechanically homogenized, followed by staining for surface molecules using LIVE/DEAD fixable Aqua (Invitrogen, 1:1000 dilution) and anti-CD4 PE-Cy5 (RPA-T4, BD, 1:50 dilution), anti-CD3 PE-Cy7 (UCHT1, eBioscience, 1:50 dilution), anti-CD45RA V450 (H100, eBioscience, 1:100 dilution), anti-CXCR5 conjugated with Alexa Fluor 488 (RF8B2, eBioscience, 1:50 dilution), Alexa Fluor 647 (RF8B2, BD, 1:50 dilution), or biotin (RF8B2, BD Biosciencese, 1:50 dilution)/streptavidin APC-Cy7 (1:400 dilution), anti-PSGL-1 PE (KPL-1, BD, 1:50 dilution) or APC (FLEG, eBioscience, 1:50 dilution), anti-ICOS FITC (C398.4A, eBioscience, 1:50 dilution), anti-CCR7 FITC (150503, R&D Systems, 1:50 dilution), anti-CD62L FITC (DREG56, eBioscience, 1:50 dilution), anti-CXCR4 PE-Cy5 (12G5, eBioscience, 1:50 dilution), anti-CD200 APC (OX104, eBioscience, 1:50 dilution), anti-OX40 PE-Cy5 (ACT35, BD, 1:50 dilution), anti-PD-1 PE-Cy7 (EH12.1, BD, 1:50 dilution), anti-CXCR3 BV421(1C6/CXCR3, BD, 1:50), anti-IL-2RA PE (M-A251, BD, 1:25), anti-CD19 APC-Cy7 (SJ25C1, eBioscience, 1:50 dilution), anti-IgD PE-Cy7 (IA6-2, BD, 1:50 dilution), anti-CD38 V450 (HIT2, BD, 1:50 dilution), and anti-IL-10R PE (3F9, Biolegend, 1:50 dilution).

Kim S.T., Choi J.Y., Lainez B., Schulz V.P., Karas D.E., Baum E.D., Setlur J., Gallagher P.G, & Craft J. (2018). Human Extrafollicular CD4+ T Helper Cells Help Memory B Cells Produce Immunoglobulins. Journal of immunology (Baltimore, Md. : 1950), 201(5), 1359-1372.

+ Open protocol

+ Expand

Multiparametric Flow Cytometry for Myeloma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bone marrow samples were divided into 2 tubes. The first tube was used to measure the MM burden in bone marrow. Cells were stained with anti-CD45-V500 (662912; BD), anti-CD19-PE-Cy7 (560728; BD), anti-CD138-APC (347193; BD), anti-CD38-V450 (562444; BD) and anti-CD56-APC-Cy7 (362512; BioLegend) for 30 min. After fixation and permeabilization, the cells were then stained with anti-clambda-PE (555797; BD) and anti-ckappa-FITC (555791; BD). Data were collected using FACS Canto II flow cytometer (BD, USA), and a minimum of 1 × 10⁶ cells were acquired per sample. MM cells were analyzed according to the report by the European Myeloma Network [44 (link)]. Minimal residual disease (MRD) was defined according to international consensus guidelines and MRD negativity was defined as less than 0.01% nucleated cells [45 (link)].
The second tube was used to detect BCMA and CD38 expression on MM cells. Cells were stained with anti-CD45-V500 (662912; BD), anti-CD19-PE-Cy7 (560728; BD), anti-CD138-V450 (562935; BD), anti-CD56-PerCP-Cy5.5 (560842; BD), anti-CD38-APC (555462; BD) and anti-BCMA-PE (130-117-544; Miltenyi Biotec). BCMA and CD38 expression was reported as the percentage of positive cells in CD45⁺ CD138⁺ CD19⁻ cells. Data were collected using FACSCanto II flow cytometer (BD, USA), and data were analyzed using FlowJo software (TreeStar, USA).

Mei H., Li C., Jiang H., Zhao X., Huang Z., Jin D., Guo T., Kou H., Liu L., Tang L., Yin P., Wang Z., Ai L., Ke S., Xia Y., Deng J., Chen L., Cai L., Sun C., Xia L., Hua G, & Hu Y. (2021). A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Journal of Hematology & Oncology, 14, 161.

+ Open protocol

+ Expand

Immunophenotyping of Myeloid Malignancies

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 5 £ 10 5 PBMCs were initially labeled with either anti-MUC1 SEA antibody DMB5F3 (murine ascites diluted to 1/200) or anti-MUC1 tandem repeat antibody HMFG1 diluted to 1/200 in PBS, followed by phycoerythrin (PE)-conjugated goat F(ab')2 anti-mouse IgG (Beckman Coulter Immunotech, Marseille, France). To characterize AML cells, anti-CD14 PECy7 (BioLegend, San Diego, CA), anti-CD34 APC, anti-CD38 V450, and anti-CD34 APC (all three from BD Biosciences, Le Pont de Claix, France) were reacted with cells. To specifically identify CMML cells, a battery of antibodies to CMML-associated antigens was used, including anti-CD16 FITC, anti-CD56 PercpCy5.5, and anti-CD45 APC (all three from BD Biosciences) and anti-CD14 PB (BioLegend). To identify AML presumed stem cells, a cocktail of lineage-specific FITC-labeled antibodies (anti-CD3, CD14, CD16, CD19, CD20, and CD56) as well as anti-CD34 and anti-CD38 (all from BD Biosciences) was used.

Guillaume T., Dehame V., Chevallier P., Peterlin P., Garnier A., Grégoire M., Pichinuk E., Rubinstein D.B, & Wreschner D.H. (2019). Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Experimental hematology, 70.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!